Nuclear Factor Erythroid 2-Related Factor 2 in Regulating Cancer Metabolism

0533049 - FGÚ 2021 RIV US eng J - Článek v odborném periodiku
Smolková, Katarína - Mikó, E. - Kovács, T. - Leguina-Ruzzi, Alberto A. - Sipos, A. - Bai, P.
Nuclear Factor Erythroid 2-Related Factor 2 in Regulating Cancer Metabolism.
Antioxidants & Redox Signaling. Roč. 33, č. 13 (2020), s. 966-997. ISSN 1523-0864. E-ISSN 1557-7716
Grant CEP: GA MZd(CZ) NV19-01-00101
Institucionální podpora: RVO:67985823
Klíčová slova: NRF2 * cancer * cancer metabolism * reactive species
Obor OECD: Biochemistry and molecular biology
Impakt faktor: 8.401, rok: 2020
Způsob publikování: Open access
https://www.liebertpub.com/doi/10.1089/ars.2020.8024

Recent Advances: The noncanonical activation of NRF2 was recently discovered, and members of this pathway are involved in carcinogenesis. Further, cancer-related changes (e.g., metabolic flexibility) that support cancer progression were found to be redox- and NRF2 dependent.
Critical Issues: NRF2 undergoes Janus-faced behavior in cancers. The pro- or antineoplastic effects of NRF2 are context dependent and essentially based on the specific molecular characteristics of the cancer in question. Therefore, systematic investigation of NRF2 signaling is necessary to clarify its role in cancer etiology. The biggest challenge in the NRF2 field is to determine which cancers can be targeted for better clinical outcomes. Further, large-scale genomic and transcriptomic studies are missing to correlate the clinical outcome with the activity of the NRF2 system.
Future Directions: To exploit NRF2 in a clinical setting in the future, the druggable members of the NRF2 pathway should be identified. In addition, it will be important to study how the modulation of the NRF2 system interferes with cytostatic drugs and their combinations.

Trvalý link: http://hdl.handle.net/11104/0311549